It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino ...

Multiple US health systems have been awaiting the authorization before taking the Queen of Hearts platform live.

Doing TAVI first was noninferior to a PCI-first strategy, with experts pointing out that each timing has its advantages.

Mirvat Alasnag talks with host Yael L. Maxwell about the need to prove herself, social media, and partnerships with patients.

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.

The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.

Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...

While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...